Latest news with #SanFrancisco
Yahoo
2 hours ago
- Entertainment
- Yahoo
Congratulations Pouring In For Christian McCaffrey On Monday
Congratulations Pouring In For Christian McCaffrey On Monday originally appeared on The Spun. Congratulations are pouring in for NFL running back Christian McCaffrey on Monday. The San Francisco 49ers star running back and his wife, swimsuit model Olivia Culpo, welcomed their first child into the world. The happy couple announced the big news on their Instagram page on Sunday. Advertisement McCaffrey and Culpo welcomed a baby girl into the world. "Colette Annalise McCaffrey 🤍," the swimsuit model announced on Sunday evening. Congratulations are now pouring in for the veteran NFL running back and his wife, as they've had some big news ahead of the 2025 regular season. LANDOVER, MARYLAND - DECEMBER 31: Christian McCaffrey #23 of the San Francisco 49ers rushes the ball against the Washington Commanders at FedExField on December 31, 2023 in Landover, Maryland. (Photo by)NFL fans are congratulating Christian McCaffrey and Olivia Culpo on the birth of their daughter. "Awwwwww congrats💕💕💕," Brock Purdy's wife, Jenna, said on Monday. "Congratulations 🥹🤍🎀," one fan added. "Congrats 🎉👼🏽🙌🏾❤️," another fan added. "Welcome earthside little Colette! ❤️❤️," one fan added. Advertisement "Awwwwww. She's perfect! Congrats ❤️," another fan added. "Colette you have no idea how loved you are already! The luckiest little lady with two of the best to call mom & dad 🤍 LOVE YOU ALL!!!" one fan added. "I knew it would be a girl!! She is a beautiful angel. love you guys," one fan added. "Oh sweet girl you are so loved already. Welcome to the world angel. Love y'all so much. 💞💞💞," one fan added. "So happy for you!!! Such a beautiful blessing! Congratulations! Hope deliver was so smooth!" another fan wrote. It's glorious news for Christian McCaffrey and his wife on the eve of the 2025 NFL regular season. Advertisement The 49ers star will now be playing for a family of three. Congratulations Pouring In For Christian McCaffrey On Monday first appeared on The Spun on Jul 14, 2025 This story was originally reported by The Spun on Jul 14, 2025, where it first appeared.
Reuters
2 hours ago
- Business
- Reuters
As class action trial looms, Meta and Flo could face 'mind-boggling' damages
July 15 (Reuters) - It's hard to imagine more intimate queries than those that fertility tracking app Flo allegedly asked its users. Among them: When was your last period? How often do you have sex? Masturbate? Do you get yeast infections? As app maker Flo Health and co-defendant Meta are set to face a class action trial in San Francisco federal court next week for allegedly violating the privacy of millions of Flo users, the question now is whether the companies will cut a deal or risk what Flo on appeal, opens new tab termed "mind-boggling" damages. Litigators sometimes bandy about the phrase 'bet-the-company case,' but this could be the real thing. Facebook parent Meta is defending against claims of violating the California Invasion of Privacy Act, which carries statutory penalties of $5,000 per violation. That would add up to at least $190 billion in damages if, as plaintiffs have previously suggested, opens new tab, there are 38 million class members. If each app entry is treated as a separate violation, total damages could be quadrillions of dollars — "a sum so large it may as well be infinite," as Flo put it. A spokesperson for Meta, which is represented by outside counsel from Latham & Watkins and Gibson, Dunn & Crutcher, said the plaintiffs' claims against the company "are simply false, and we are confident that the evidence at trial will demonstrate the realities." Flo, represented by Dechert, separately is dealing with claims including violations of California's Confidentiality of Medical Information Act, which carries penalties of $1,000 per violation. A spokesperson for the London-based, privately held company said Flo "is committed to protecting the privacy of its users, and any allegation otherwise has no merit." The companies have argued that Flo's privacy disclosures gave users notice of the alleged misconduct and that they impliedly consented, that the shared data did not contain personally identifying information and that Meta never 'intended' to intercept communications. According to the Meta spokesperson, the company does 'not want health or other sensitive information' and its terms 'prohibit developers from sending any.' Google, which was also named in the suit, reached a settlement in principle last week on as-yet undisclosed terms. A Google spokesperson did not respond to my request for comment. Given the risk of outsized verdicts (even those that don't involve 16 figures), class actions rarely go to trial. For example, Google last month took a chance on one involving cellular phone data, only to be hit with a $314 million verdict by a California jury on July 1. The Flo plaintiffs invoke California's 1967 invasion of privacy law, a Cold War relic that makes it illegal to covertly eavesdrop or record telephone conversations. As I previously wrote, the cause of action has enjoyed a resurgence of late among plaintiffs' lawyers, especially in connection with the use of chatbots, tracking pixels and other data analytics software. The Flo jury trial, set for July 21 before U.S. District Judge James Donato, looms as current and former Meta leaders face an $8 billion shareholder suit in Delaware that kicks off Wednesday. The shareholders allege Meta executives violated a 2012 agreement between Facebook and the Federal Trade Commission to protect users' data, my Reuters colleague Tom Hals reports. The Flo class action also has its roots in an FTC case. The agency sued Flo, opens new tab after The Wall Street Journal in 2019 reported that it was able to intercept identifying health information about Flo users transmitted by the app to Facebook. The FTC's 2021 settlement required Flo to obtain users' consent before sharing their health information and to notify affected women about the disclosure. According to the follow-on class action, opens new tab, which covers all Flo app users nationwide from Nov. 1, 2016, to Feb. 28, 2019, plus a California subclass, Flo integrated code from Meta and Google's software development kits, which are used for data analytics, into its app. That allegedly allowed the companies to review personal information on users' menstrual cycles, sex lives and pregnancies, despite promises by Flo that the data would remain confidential. The third parties were "were free to use this data for their own purposes," including marketing and advertising, the complaint alleges. "If Plaintiff and Class members had known that Flo Health would share their intimate health data, they would not have used the Flo App." Plaintiffs' lawyers from Labaton Keller Sucharow; Lowey Dannenberg and Spector Roseman & Kodroff did not respond to requests for comment. Donato certified the class in May, writing, opens new tab that the 'loss of control over one's personal information' is a concrete harm, "whether from stealing access to a personal diary in 1916 or obtaining user information in a healthcare app in 2016.' The decision prompted an interlocutory appeal, opens new tab in June by Flo to the 9th U.S. Circuit Court of Appeals. Flo argued that Donato wrongly held that the company's class action waiver was unenforceable. The judge deemed the provision unconscionable because it was buried in Flo's terms of service. Flo also argued that the company's use of the software development kits is 'a practice as unremarkable as it is widespread,' and that it disclosed using the kits in its privacy policy and terms of service. Flo also said the transmitted data was de-identified, consisting of alphanumeric strings corresponding to the device on which the app was used. The appeals court in six-sentence order, opens new tab on June 17 denied Flo's petition and declined to stay the lower court proceedings. 'Cases of this magnitude almost never proceed to trial,' Flo noted in its appeal, describing the 'hydraulic pressure' to settle. I can only imagine. But if it does indeed go to trial, all I can say is, pass the popcorn.
Reuters
4 hours ago
- Business
- Reuters
Hims & Hers hit with investor lawsuits after Novo ends Wegovy partnership
July 15 (Reuters) - Telehealth company Hims & Hers (HIMS.N), opens new tab is facing a growing number of U.S. investor lawsuits after Novo Nordisk's ( opens new tab decision last month to end a short-lived partnership to sell its Wegovy weight-loss drug through the platform sent shares plunging. A group of shareholders sued Hims on Monday in federal court in San Francisco, accusing its board and senior executives of making false and misleading statements about its financial condition and operations. The case was filed as a so-called derivative lawsuit on behalf of the company. The lawsuit follows two securities class actions filed by Hims investors in the same court last month, seeking damages over the drop in stock price after Novo in late June ended what the companies had initially described as a long-term collaboration designed to make obesity care and treatment more affordable and accessible. Hims, Novo and the lawyers who filed Monday's lawsuit did not immediately respond to requests for comment. Danish drugmaker Novo is not a defendant in the lawsuits. Founded in 2017, San Francisco-based Hims provides health and wellness products focused on weight loss, sexual and mental health and hair loss. Novo on June 23 said it was ending their partnership that began in late April, citing Hims' alleged improper marketing and sales of Wegovy copies. Novo accused Hims of 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.' Hims CEO Andrew Dudum responded, opens new tab in a post on X that day that accused Novo management of misleading the public and making anticompetitive demands 'that infringe on the independent decision making of providers and limit patient choice.' Hims shares fell $22.24, or over 34%, after Novo's announcement, declining from $64.22 per share on June 20 to close at $41.98 per share on June 23. The stock closed on Monday at $52.03 a share. The tight supply of Wegovy in the United States had allowed Hims and others to sell cheaper, compounded versions of the drug, known chemically as semaglutide. The U.S. Food and Drug Administration in February removed Wegovy from the agency's shortage list. Hims said the decision meant it could not guarantee continued sales of compounded semaglutide. The case is Steve Jones v. Andrew Dudum, U.S. District Court, Northern District of California, No. 3:25-cv-05866-AGT. For plaintiff: Shane Rowley of Rowley Law PLLC, and Francis "Casey" Flynn Jr. of Law Office of Francis J. Flynn Jr For defendants: No appearances yet Read more: Novo, Hims & Hers engage in war of words after Wegovy deal falls apart US judge upholds FDA's removal of Ozempic, Wegovy from drug shortage list Novo Nordisk to sell Wegovy through telehealth firms to cash-paying US customers
The Independent
5 hours ago
- Automotive
- The Independent
San Francisco drivers ticketed while parking in own driveways
A group of frustrated San Francisco residents is sick of receiving tickets despite being parked in their own driveways. Some of the residents in the California city say they are convinced that someone is using old photos to file citations against them over and over again. Larry Reed told NBC Bay Area that he found a $108 ticket on his car on Monday. 'One hundred and eight dollars for parking on my driveway,' he told the broadcaster. A complaint had been filed against his car for parking on the sidewalk, part of a flood of complaints that have been made against him and his neighbors, which have resulted in hefty parking fines. "We don't know what the deal is. It's just, when we park on the driveway, we get a notice,' Yolanda Francisco told the broadcaster. 'It's been reported to 311 multiple times. But one picture, multiple times." The citations have been happening for about two months in Mission District neighborhoods. According to parking officers who spoke to the broadcaster, they're responding to complaints filed on the city's 311 system. Francisco's son-in-law, David Chen, noted that the photos of the alleged infractions are repeats, showing the same alleged parking violations over and over again. Chen was there when Reed received his citation on Monday. He said Reed's car — while slightly on the sidewalk — left plenty of space for anyone, including people with mobility issues, to get past. "There's like 10 feet of open space. It's not causing a problem for anyone with accessibility issues,' he told the broadcaster. 'It's literally somebody making themselves feel good by submitting it, trolling us, getting us tickets." Reed has gone so far as to post a sign near his front steps offering to move his vehicle for anyone who has an issue with its location — they need only call him. Sharon Gillenwater, another resident living in the Noe Valley neighborhood, said she was fined a total of $324 because her son's car and her SUV slightly cross their driveway line onto the sidewalk when they're parked, according to the U.S. Sun. She called the fines "overzealous punishment" and agrees with the idea that someone is intentionally targeting people in the neighborhoods with their reports. 'We're not fighting the law, we all agree that strollers and disabled people need to pass," she told the publication. 'But can we just be in the spirit of the law? In our case, there is plenty of room for two wheelchairs to go in tandem down the street.' The San Francisco Municipal Transportation Agency said it is not targeting the residents, but is just responding to 311 reports as they are received. Reed and his neighbors are frustrated with the sudden flood of complaints, and they want to know why, all of a sudden, someone has raised a stink about their parking.
Yahoo
5 hours ago
- Business
- Yahoo
Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis
SOUTH SAN FRANCISCO, Calif., July 15, 2025--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Division of Hepatology and Nutrition of the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the completed PORTOLA Phase 2a clinical trial evaluating zetomipzomib, a first-in-class selective immunoproteasome inhibitor, in patients with autoimmune hepatitis (AIH). "We are pleased that the FDA has lifted the partial clinical hold on zetomipzomib in AIH after their review of our comprehensive safety assessment of the zetomipzomib program," said Chris Kirk, PhD, CEO and co-founder of Kezar. "We continue to believe that zetomipzomib has the potential to positively transform the lives of patients living with AIH. We look forward to engaging with the FDA to align on the design of the next clinical trial of zetomipzomib in AIH." Although Kezar has suspended development of zetomipzomib in lupus nephritis (LN) to focus on AIH, the company met with the Independent Data Monitoring Committee (IDMC) for the previously terminated PALIZADE clinical trial to review the safety profile of zetomipzomib. The IDMC has provided Kezar with recommendations for conducting future clinical trials in LN. Based on this feedback and internal analysis of safety data across all clinical studies involving zetomipzomib, Kezar plans to respond to the FDA Division of Rheumatology and Transplant Medicine with a request to lift the clinical hold on zetomipzomib in LN. About Zetomipzomib Zetomipzomib is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases. Preclinical research demonstrates that selective immunoproteasome inhibition results in a broad anti-inflammatory response in animal models of several autoimmune diseases, while avoiding immunosuppression. Data generated from completed clinical trials provide evidence that zetomipzomib exhibits a favorable safety and tolerability profile for development in severe, chronic autoimmune diseases. About Autoimmune Hepatitis Autoimmune hepatitis (AIH) is a rare chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage, severely impacting patients' physical health and quality of life. Lifelong maintenance therapy is required to avoid relapse and burdensome adverse effects. If left untreated, AIH can lead to cirrhosis, liver failure and hepatocellular carcinoma. In the United States, AIH affects approximately 100,000 individuals, with incidence rates increasing. The cause of this condition remains unclear, with females affected four times as often as males. Currently, standard of care treatment for AIH is chronic, immunosuppressive treatment with corticosteroids that frequently cause life-altering side effects, including diabetes, osteoporotic fractures and cataracts. There is a significant need for treatment regimens that reduce or remove the need for chronic immunosuppression from use of corticosteroids. About Kezar Life Sciences Kezar Life Sciences is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases. Zetomipzomib, a selective immunoproteasome inhibitor, is currently being evaluated for autoimmune hepatitis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. For more information, visit and follow us on LinkedIn, Facebook, Twitter and Instagram. Cautionary Note on Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "can," "should," "expect," "believe," "potential," "anticipate" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Kezar's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Kezar's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the timing and outcome of regulatory submissions and interactions with the FDA, EMA or any other regulatory agencies with respect to zetomipzomib or Kezar's clinical trials, the initiation of an additional clinical trial of zetomipzomib in AIH, and expectations regarding the removal of the clinical hold of zetomipzomib in LN, and the likelihood of obtaining regulatory approval of zetomipzomib. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during clinical studies, difficulties enrolling and conducting our clinical trials, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, and unexpected litigation or other disputes. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Kezar's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" contained therein. Except as required by law, Kezar assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. View source version on Contacts Investor and Media Contact:Gitanjali JainSenior Vice President, Investor Relations and External AffairsKezar Life Sciences, Melden Sie sich an, um Ihr Portfolio aufzurufen.
